Both hemodynamic abnormalities and thrombophilia predispose to pregnancy-associated vaswlar complications such as fetal growth restriction, stillbirth, preeclampsia, and placental abruption. Antithrombotic treatment may reduce the risk for these events. In this study we tested the hypothesis that in normotensive thrombophilic formerly preeciamptic women certain alteration5 in hemodynamic function a5 measured under nonpregnant conditions predict the development of hypertensive di50rders and/o r fetal growth re5triction in the 5ub5equent pregnancy.
years, evidence is accumulating that particularly preexisting vascular, metabolic, or clotting disorders predispose to hypertensive complications in pregnancy. [3] [4] [5] [6] [7] [8] The latter suggests that in these cases the preexistent disorder predisposes for "endothelial decompensation" in pregnancy, the common end point of different pathogenetic pathways in pregnancy-related hypertensive syndromes. 9 Recently, we observed in formerly preeclamptic women that a low plasma volume prior to pregnancy predisposes to recurrence of a hypertensive disorder in a next pregnancy. 8 Unfortunately, the predictive value of a subnormal plasma volume was modest, probably because gestational vascular complications may result from a wide variety of hemodynamic, clotting, and mixed disorders. The latter indicates that in formerly preeclamptic women, stratification for potential underlying pathophysiologic ally distinct disorders may improve the value of subnormal plasma volume and that of other markers in predicting recurrence of hypertensive disease and/or placental insufficiency in a next pregnancy.
Thrombophilia, a condition that predisposes to thromboembolic disease, is associated with an increased risk for hypertensive complications in pregnancy, including placental insufficiency3-6,lO Although antithrombotic prophylaxis in these women may reduce the risk to develop these complications, it is unlikely to ameliorate concomitant non thrombotic risk conditions. 11 Taking a preexistent risk condition as a starting point, 6 the following questions may be addressed: First, what is the recurrence rate of hypertensive complications in a subsequent pregnancy for certain identifiable risk conditions? Second, is the presence of more than one disorder associated with a higher recurrence rate of hypertensive complications in pregnancy?
The objective of the present study was to test the hypothesis that in normotensive thrombophilic formerly preeclamptic women, hemodynamic, metabolic, and volume variables determined before pregnancy are clinically relevant for predicting recurrent hypertensive disorders and/or fetal growth restriction in a next pregnancy, To this end, we determined in formerly preeclamptic women, clotting function, central hemodynamic variables, and plasma volume before the next pregnancy, Then, we registered the recurrence rate of hypertensive complications and/or fetal growth restriction in that next pregnancy. Finally, we determined the predicted value of each marker determined before that pregnancy. All participating thrombophilic women received, based on the underlying disorder, prophylactic medication, either low molecular weight heparins and/or piridoxine and folic acid.
METHODS

Selection of Patients
A total of 350 formerly preeclamptic, nondiabetic women participated in this study. Data acquisition was initiated at least 5 months postpartum. Formerly preeclamptic women were recruited from our outpatient clinic at the postpartum followup, Preeclampsia (gestational), hypertension, and the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) were defined according to the criteria of the National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. 1 We defined fetal growth restriction on the basis of the birth of a baby with a neonatal birth weight below the tenth centile according to Dutch centiles set by Kloosterman. Measurement of the 24-hour urinary sodium output on the day before the experiment was performed to estimate sodium intake. None of the participants used vitamin supplements or any other medication in the 2 weeks before measurement. Women on anti-J Soc Gynecol Investig Vol. 12 Figure 1 . Management, subdivision, and treatment of fomlerly preeclamptic participants.
hypertensive drugs discontinued this medication at least 1 week prior to the study session. After an overnight fast, participants were tested for thrombophilia, and hemodynamic and metabolic function. Thrombophilia was defined as a condition characterized by the presence of at least one clotting disorder known to be associated with an increased risk of venous thromboembolism. Inclusion for final analysis required the establishment of an ongoing (>16 weeks' gestational age) singleton pregnancy within 1 year after the pre-pregnant measurements in a normotensive thrombophilic formerly preeclamptic women. As a consequence, 47 formerly preeclamptic women could be included for final analysis. After the measurement sessions, formerly preeclamptic women were managed as illustrated in Figure 1 . All subjects were Caucasian. Those who smoked refrained from smoking during pregnancy. All participants gave written informed consent. The hospital's medical ethical committee approved the study.
Experimental Procedure
The methodology of the measurements and calculations with respect to the thrombophilic screening and hemodynamic function have been detailed elsewhere. 6 THROMBOPHILIC SCREENING. In short, we measured the presence oflupus anticoagulant and anticardiolipin antibodies. We defined the antiphospholipid syndrome as the condition where the titers of the circulating anti cardiolipin antibodies were higher than 15 GPL for IgG antiphospholipid antibodies and 20 MPL for IgM antiphospholipid antibodies. Coagulation tests were performed after a venous puncture. After elimination of platelets, samples were stored at -80C prior to assay. In these samples we determined protein C activity, total protein S antigen and free protein S, activated protein C resistance, and antithrombin activity. A methionine-loading test was used to diagnose hyperhomocysteinemia. During the test participants consumed a standard low-methionine breakfast and lunch.
MEASUREMENT OF CENTRAL HEMODYNAMIC FUNCTION. In the midfollicular phase (day 5 : : : ' : : : 2) of the menstrual period the measurement session started at 9 AM after sampling of the clotting variables. Participants did not drink caffeine-or alcohol-containing beverages and refrained from smoking and eating for at least 10 hours before the experiment. Throughout the measurement session, subjects were in halfsupine position on a comfortable chair. Arterial blood pressure and heart rate were recorded intermittently by a semiautomatic oscillometric device (Dinamap Vital Signs Monitor 1846; Critikon, Tampa, FL), interrupted only during blood sampling. Urinary sodium concentration was measured in a urine sample collected over the 24 hours preceding the measurement session. All variables were measured by standard chemical procedures.
MEASUREMENT OF PLASMA VOLUME. Plasma volume was measured using the iodine 125-albumin C 25 I-HSA)
indicator dilution method and expressed in milliliters per kilogram (mLlkg) lean body mass (LBM).6
ECHOCARDIOGRAPHY. Echocardiography (ECG) to assess cardiac function was performed in the semi-left lateral position, after completion of the plasma volume measurement and after 5 minutes rest, using a cross-sectional, phased-array ECG Doppler system (Hewlett-Packard Sonos 2500, Andover, MA.6 Cardiac output (L . min -1) was calculated by multiplying stroke volume (mL) and heart rate (bpm). In this formula, heart rate was obtained by taking the reciprocal of the mean of five consecutive R-R intervals on the ECG. Stroke volume was calculated by multiplying the aortic velocity integral and the aortic area. Aortic flow was measured across the aortic valves from an apical approach. 6 Total peripheral vascular resistance (dyne' s . cm -5) and index (dyne' s . cm -s . m -2) were Spaanderman et al obtained by taking the quotient, respectively, of mean arterial pressure and cardiac output and cardiac index. The values used for mean arterial pressure were obtained during the cardiac output measurement using the recordings of the Dinamap apparatus and were calculated as the mean of three consecutive recordings.
ST ATISTICAL ANALYSIS. Data are presented as medians and ranges unless stated otherwise. Intragroup differences were tested with the Wilcoxon signed-ranks matched-pairs test, and differences between groups with the Mann-Whitney U test. Correlations, when calculated, between concomitantly measured potentially related variables, were tested by Speamun rank correlation analysis. A P value less than .05 was considered statistically significant. We performed a multivariate backward step wise logistic regression analysis that included as dependent variables only those that were found to be correlated between the recurrence of gestational hypertension and preeclampsia, and maternal hemodynamic variables. This analysis allowed us to identifY actual independent predictors of maternal hypertensive complications. From the independent predictors, we calculated the Mantel-Haenszel common odds ratio and 95% confidence interval. Finally, the calculated minimum detectable differences of the mean of variables within the thrombophilic group (n = 47, et = 0.05, ~ = 0.10), assuming a normal distribution of the data, were 11 % for body mass index, 6% for mean arterial pressure, 8% for heart rate, 9% for plasma volume, 11% for cardiac output, 9% for cardiac index, 11 % for total peripheral vascular resistance and its index, 3 weeks in gestational age at delivery, 595 g in birth weight, and a difference of 15 in centile, respectively.
RESULTS
Of the 350 eligible formerly preeclamptic participants, 47 normotensive thrombophilic formerly preeclamptic women were available for final analysis. Thirty-eight thrombophilic formerly preeclamptic women had one thrombophilic disorder, and nine had more than one. Twenty-four of 47 developed at least gestational hypertension. They were assigned to Current pregnancy n (%) 0(0%)* 24 (100%) 0(0%)* 12 (50%)* 1 0(0%)* 12(50%)1 36 (21~39)* * Indicates the value is different from the previous pregnancy within the same subgroup (P < .05).
the COMPLITHROMB group. Those who remained normotensive throughout pregnancy were assigned to the THROMB group. The demographic characteristics of included participants are listed in Table 1 . The two subgroups of norn1Otensive thrombophilic formerly preeclamptic women and the controls were comparable with respect to age, height, parity, and urinary sodium output. COMPLITHROMB were more obese than THROMB.
Among the formerly preeclamptic women, the antiphospholipid syndrome (13/47, 28%) and hyperhomocysteinemia (24/47, 51%) were most common, followed by protein S deficiency (11/47, 23%), activated protein C resistance as a consequence of factor V Leiden mutation (6/47, 13%) and protein C deficiency (1/47, 2%). Nine formerly preeclamptic women, who were diagnosed as having the antiphospholipid syndrome, were IgG serotypes. We did identifY one woman with antithrombin deficiency. Between evaluation and subsequent ongoing pregnancy, 10 of 47 (21 %) formerly preeclamptic thrombophilic women experienced a spontaneous abortion, six in conjunction with hyperhomocysteinemia (one with an antiphospholipid syndrome as well), two in conjunction with protein S deficiency, and two with an antiphospholipid syndrome. There were no differences between type of thrombophilic disorder and the recurrence of hypertensive complications. Table 2 lists the cardiovascular data and plasma volume. In COMPLITHROMB, total peripheral vascular resistance index was higher, and plasma volume and cardiac index lower, than in THROMB.
Maternal and fetal data with respect to the preceding and subsequent pregnancies are listed in Tables 3 and 4 , respectively. Most of the outcome variables in the two formerly preeclamptic subgroups had improved markedly in the subsequent pregnancy relative to the preceding pregnancy. Nonetheless, COMPLITHROMB had a higher incidence of fetal growth restriction as indicated by lower birth weight and centile. In the whole group, as compared to the preceding complicated pregnancy, we noted a 7-week (0 to 15) prolongation of pregnancy, which contributed to an increase in neonatal weight by 1880 g (-220 to 3210) corresponding with an increase in birth weight centile 12 (-45 to 88). Ifin these formerly preeclamptic women the subsequent pregnancy was complicated by recurrent preeclampsia, the complication developed approximately 7 weeks (-5 to 14) later than in the preceding index pregnancy. Pre-pregnant plasma volume correlated inversely with the recurrence rate of gestational hypertension (r = -0.67, P <.0001), preeclampsia (r = -0.64, P <'0001), and HELLP syndrome (r = -0.37, P = .01). In addition, a low plasma volume predisposed to a lower gestational age at delivery (r = -0.31, P = .04). A receiver Previous Current pregnancy n (%) pregnancy n (%)
38 (26~41)* t 19 (82%) 1 (4%)* 22 (92%) 5(21%)*1 1170 (195~3260) 3440 (2330~4240)* 980 (335~3720) 3000 (480~3780)* t 15 (1 ~70) 44 (4~95)* 5(1~90)t 25 (2~96)* t 6 (26%) 5 (22%) 14 (58%) 1 6 (25%)* 5 (22%) 0(0%)* 6 (25%) 0(0%)* operating characteristic (ROC) curve to explore the predictive potential of the pre-pregnant plasma volume measurements indicated that normotensive thrombophilic formerly preeclamptic participants with a plasma volume below 42 mL . kg LBM -1 were at high risk to develop recurrence of preeclampsia in a subsequent pregnancy, with a sensitivity and specificity of 83% and 100%, respectively. The associated positive and negative predictive values were 100% and 95%, respectively ( Figure 2 ). Almost 80% of this population (37/47) had a plasma volume of at least 42 mL . kg LBM -1. Two of these women (5%) developed recurrent preeclampsia. Both women were suffering from the antiphospholipid syndrome. Nonetheless, over the whole population, there was no correlation between the type of thrombophilia and pregnancy outcome. A plasma volume below 49 mL . kg LBM -1 identified thrombophilic women destined to develop gestational hypertension with a sensitivity and specificity of 100% and 74%, and positive and negative predictive values of 80% and 100%, respectively (Figure 2) . In addition, we performed a multivariate backward logistic regression analysis in which body mass index, plasma volume, cardiac index, and total peripheral vascular resistance index were included. After analysis, for recurrent gestational hypertension, plasma volume (P = .002) and total peripheral vascular resistance index (P = .(47) appeared to be independent risk factors, while in recurrent preeclampsia, only plasma volume remained an independent variable (P = .002). From the multivariate analysis, a regression score was computed, after which a formula was constructed to predict recurrent hypertensive complications. Comparing the predicted hypertensive problems as a function of observed hypertensive complications,
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total peripheral vascular resistance did not contribute to better predictive power. Therefore, only plasma volume was used to compute recurrence risks. The common odds ratio on hypertensive complications varied as a function of plasma volume ( Table 5 ). The chance to develop recurrent gestational hypertension can be calculated according to the formula: Pgestational hypertension = 111 + e -(15.967 -IU3 PV'"M). The chance to devel~p recurrent preeclampsia can be calculated according to the formula: P -111 + e-(23.551 -0.547 PVLBM).
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DISCUSSION
Although the underlying pathogenetic mechanisms of preeclampsia are still unclear, there is general agreement about a central role for throphoblastic factors and dysfunctional endothelium in triggering the typical clinical symptoms. 9 Trophoblastic and endothelial function can be jeopardized by numerous factors, either biochemically, such as in thrombophilia or diabetes mellitus, or mechanically, such as in hypertension. Normal pregnancy is associated with a physiologic rise in the strain exerted on the endothelium. Therefore, it is not surprising that accompanying risk factors enhance the development of vascular complications during pregnancy. In this prospective study, preexistent maternal features with extra endothelial strain as common denominator were found to predispose for recurrent hypertensive disorders in high-risk pregnancIes.
With respect to the demographic characteristics, except for a higher body mass index in the COMPLITHROMB group, the two formerly preeclamptic subgroups did not differ appreciably. A higher body mass index in formerly preeclamptic women has also been reported by others and is a well-known risk factor for both cardiovascular and metabolic complications. 12 There is substantial variation in reported incidences of thrombophilia among formerly preeclamptic women among different geographic regions in the world. However, the increased incidence of thrombophilic disorders among the formerly preeclamptic individuals in this study is in line with previous findings in Israeli and Dutch populations. 3 -5 Most previous studies on recurrence of hypertensive disorders in pregnancy are based on obstetrical history as a starting point, rather than underlying disorders. Furthermore, most of these studies were performed retrospectively, in untreated 
